New combo therapy aims to outsmart resistant breast cancer

NCT ID NCT04052555

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 3 times

Summary

This early-stage trial tests a drug called berzosertib combined with radiation therapy for people with certain types of breast cancer that no longer respond to chemotherapy. The goal is to find the safest dose and see if the combination can shrink or stabilize tumors better than radiation alone. About 42 adults with non-metastatic, HER2-negative breast cancer are taking part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILATERAL BREAST CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bilateral breast carcinoma breast cancer breast carcinoma breast neoplasm estrogen-receptor positive breast cancer Her2-receptor negative breast cancer hormone receptor-positive breast cancer progesterone-receptor positive breast cancer triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BILATERAL BREAST CARCINOMA HER2-NEGATIVE BREAST CARCINOMA LOCALIZED BREAST CARCINOMA RECURRENT BREAST CARCINOMA TRIPLE-NEGATIVE BREAST CARCINOMA

Contacts and locations

Locations

Farmington Health Center

Farmington, Utah, 84025, United States
Huntsman Cancer Institute/University of Utah

Salt Lake City, Utah, 84112, United States
Mayo Clinic Hospital in Arizona

Phoenix, Arizona, 85054, United States
Mayo Clinic in Arizona

Scottsdale, Arizona, 85259, United States
Mayo Clinic in Florida

Jacksonville, Florida, 32224-9980, United States
Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States
NYP/Weill Cornell Medical Center

New York, New York, 10065, United States
Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States
Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, 08903, United States
UPMC Hillman Cancer Center

Pittsburgh, Pennsylvania, 15232, United States
University of California Davis Comprehensive Cancer Center

Sacramento, California, 95817, United States
University of Texas Medical Branch

Galveston, Texas, 77555-0565, United States
University of Utah Sugarhouse Health Center

Salt Lake City, Utah, 84106, United States
University of Wisconsin Carbone Cancer Center - University Hospital

Madison, Wisconsin, 53792, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.